article · Zagazig University Medical Journal
Background: Psychiatric disorders negatively affect individuals’ quality of life. It is believed that latent toxoplasmosis is associated with mental illnesses and personality changes due to its neurotropic nature. Experimental evidence in rodent models and controlled behavioral studies in people that show elevated seropositivity of anti-toxoplasma antibodies in individuals with mental problems all strongly support this theory. In this study, we tried to shed light on the role of toxoplasmosis as a risk factor for some psychiatric disorders, aiming to treat those patients and improve their life performance. Methods: A case control study was performed in the psychiatry outpatient clinic, Zagazig University Hospital and Medical Parasitology Department, Faculty of Medicine, Sharkia Governorate, Egypt. This study included 152 subjects (76 patients with major psychiatric disorders and 76 healthy control subjects). The diagnosis of psychiatric disorders was according to the DSM-5 criteria for major psychiatric disorders. ELISA was used to test patients for anti-T. gondii IgG seropositivity. Results: According to our findings, psychiatric patients had a greater seroprevalence of Toxoplasma IgG (64.5%; 49/76) than the control group (13.2%; 10/76) (p<0.001). Also, patients with major depressive disorders (MDD) had the highest prevalence of latent T. gondii infection, followed by patients suffering from schizophrenia and bipolar. Conclusions: Patients with some psychiatric disorders showed higher seropositivity of anti-Toxoplasma IgG compared with the control group. This was evident in those with MDD. Understanding the risk factors for Toxoplasma infection may be the first step in developing future preventative measures for patients with mental illness.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/zumj.2024.337262.3693
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.